Vifor, Angion sign licensing agreement for drug to treat kidney complications
Click Here to Manage Email Alerts
Angion Biomedica Corp. has signed a licensing agreement with Vifor Pharma for the commercialization of ANG-3777, a drug shown to treat delayed graft function and cardiac surgery-associated AKI, according to a press release.
“This agreement highlights the leadership position that Vifor Pharma has developed in the nephrology space and the fact that it has become the company of choice for organizations committed to partnering innovative nephrology focused assets,“ Stefan Schulze, CEO of Vifor Pharma, said in the release. “Angion is an excellent partner with an outstanding expertise leading to the development of this exciting asset and other pipeline products.”
According to the release, Angion will be responsible for all ongoing clinical development programs, while Vifor Pharma will be in charge of commercialization.
Jay Venkatesan, MD, president and CEO of Angion, also commented on the agreement in the release.
“This is a major milestone for the team at Angion who has worked for many years to develop ANG-3777 as a therapy for patients with acute kidney injuries,” he said. “We look forward to phase 3 data in [delayed graft function] DGF towards the end of 2021 and working with Vifor Pharma to potentially bring ANG-3777 to nephrology patients worldwide.”
ANG-3777 operates by mimicking the biological activity of hepatocyte growth factor thereby “activating critical pathways in the body’s natural organ repair process,” according to the release, with Schulze adding that delayed graft function and cardiac surgery-associated AKI are “both critical conditions, currently without any effective or approved therapies.”
Read more about
Click Here to Manage Email Alerts